HOVON 151 (R/R)

A phase II study evaluating the feasibility and clinical efficacy of atezolizumab consolidation treatment in high risk diffuse large B-cell lymphoma

Study treatment

• Atezolizumab 1200mg day 1, q3 weeks until relapse

Inclusion criteria

• Age 18-75 years
• confirmed histologic diagnosis of diffuse large B-cell lymphoma (DLBCL-NOS)
• Ann Arbor stages II-IV
• WHO performance score 0-1
• IPI score  ≥ 3 at diagnosis
• Complete metabolic remission after 6-8 cycles of R-CHOP according to the Lugano criteria

Exclusion criteria

• Significant renal dysfunction
• Inadequate hematological function: hemoglobin < 5,5 mmol/L, ANC < 1,0 x 10^9/L or platelets < 75 x 10^9/L
• Spontaneous INR > 1.5, aPTT > 33
• Significant hepatic dysfunction (total bilirubin  ≥ 1.5 x ULN or transaminases ≥ 2.5 x ULN)
• Major surgery within the last 4 weeks
• Prior treatment with atezolizumab, or anti PD-1 or PDL-1 antibodies
• Prior treatment with CD137 agonists or immune checkpoint blockade therapies, includinganti-CTLA4 therapeutic antibodies
• Treatment with systemic immunostimulatory agents

Participating sites

• University Hospital Leuven Gasthuisberg
• Algemeen ziekenhuis St-Jan Brugge
• Universitair ziekenhuis Antwerpen
• AZ Delta Roeselare
• ZNA